drugset / Trial / NCT00307723
Study of Bevacizumab in Combination With 5-FU, Oxaliplatin and External Beam Radiation Followed by Gemcitabine and Bevacizumab for Locally Advanced Pancreatic Cancer
Phase 1/2
Terminated
52 enrolled
Massachusetts General Hospital
Beth Israel Deaconess Medical Center · collabDana-Farber Cancer Institute · collabGenentech, Inc. · collabSanofi · collab
Non-randomizedFactorialOpen-labelTreatment
Summary
The purpose of this study is determine the safety of bevacizumab, oxaliplatin, 5-FU, and gemcitabine in combination with external beam radiation therapy(Phase I portion) as well as to begin to collect information about whether this combination treatment is effective in treating patients with locally advanced pancreatic cancer (Phase II portion).
Timeline
- Start
- 2006-05
- Primary completion
- 2007-08
- Completion
- 2009-07
Outcome
Outcome not reported
Stopped (Enrollment): “poor accrual”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | — | Intravenous |
| Subject | Gemcitabine | Small molecule | — | Intravenous |
| Subject | Oxaliplatin | Small molecule | — | Intravenous |
| Subject | fluorouracil | Small molecule | — | — |